Our collective results support the utility of combination therapy involving EZH2 inhibition and pomalidomide for EZH2-mutated DLBCL and provide insights into the mechanisms underlying tumor suppression activity. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.